Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | Director | July 28, 2022 | August 01, 2022 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director | May 07, 2026 | May 11, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date July 28, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,246 |
Reported balance
After 2022-07-28 transaction · row 1
1 source rowRow 1 · 2022-07-28 · Grant · Acquired 32,400 · Balance 259,246 F1: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2032-07-28 | Direct | 47,600 |
Reported balance
After 2022-07-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-07-28 · Grant · Acquired 47,600 · Balance 47,600 F2: The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 1,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 1,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 1,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 1,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 1,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 1,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 5,000 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2: The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,700 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 17,700 · Balance 17,700 F1: Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock. F2: RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. The reporting person elected to defer receipt of the shares underlying the RSUs. In accordance with his deferral election, vested shares will be delivered to the reporting person in one lump sum, in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs (unless the reporting person elected a later calendar year). |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock.
F2: RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. The reporting person elected to defer receipt of the shares underlying the RSUs. In accordance with his deferral election, vested shares will be delivered to the reporting person in one lump sum, in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs (unless the reporting person elected a later calendar year).
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 25,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 11, 2026 20:37 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 17,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001214496-26-000001 · wk-form4_1778531820.xml · derivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,700 Underlying: Common Stock · 17,700 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock. F2 · derivative.exercise_date: RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. The reporting person elected to defer receipt of the shares underlying the RSUs. In accordance with his deferral election, vested shares will be delivered to the reporting person in one lump sum, in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs (unless the reporting person elected a later calendar year). F2 · derivative.expiration_date: RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. The reporting person elected to defer receipt of the shares underlying the RSUs. In accordance with his deferral election, vested shares will be delivered to the reporting person in one lump sum, in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs (unless the reporting person elected a later calendar year). Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 19,592 | $0.00 | $0.00 |
DisclosureSEC source: 0000917520-25-000044 · wk-form4_1747167452.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,034 Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 6,939 | $0.00 | $0.00 |
DisclosureSEC source: 0000917520-25-000044 · wk-form4_1747167452.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,442 Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000950170-24-076265 · ownership.xml · derivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:38 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 8,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-022923 · wk-form4_1715632673.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,503 Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 16:57 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 512,848 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000950170-24-013351 · ownership.xml · derivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,848 Underlying: Common Stock · 512,848 shares Expires 2034-02-06 F1 · derivative.exercise_date: The option vested and became exercisable as to 14.28% of the underlying shares on February 7, 2024 and vests and will become exercisable in thirty-six (36) substantially equal monthly installments thereafter, such that the option shall be fully vested and exercisable on February 7, 2027, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 16:21 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 36,713 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0000950170-23-032670 · ownership.xml · derivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,713 Underlying: Common Stock · 36,713 shares Expires 2023-07-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. Read SEC document |
| July 10, 2023 Filed Feb 9, 2024 17:00 UTC Amendment | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 36,713 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0000950170-24-013362 · ownership.xml · derivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,713 Underlying: Common Stock · 36,713 shares Expires 2033-07-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 4,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029792 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,807 Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 47,600 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001104659-22-084772 · tm2222147-9_4seq1.xml · derivative · entry 9 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 Underlying: Common Stock · 47,600 shares Expires 2032-07-28 F2 · derivative.exercise_date: The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 32,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-084772 · tm2222147-9_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,246 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 21:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 65,770 | $0.81 | $52,944.85 |
DisclosureSEC source: 0001104659-22-069015 · tm2217848-4_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,846 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 180,934 restricted stock units. Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 37,500 | $0.64 | $24,123.75 |
DisclosureSEC source: 0001104659-22-062916 · tm2216022-1_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,616 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6245 to $0.6675, inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029707 · doc4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,321 Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029707 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,865 Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 427,700 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033393 · tm229119-5_4seq1.xml · derivative · entry 9 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,700 Underlying: Common Stock · 427,700 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 100,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033393 · tm229119-5_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,116 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 33,366 shares on March 10, 2023, (ii) 33,367 shares on March 10, 2024 and (iii) 33,367 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 21,644 | $1.74 | $37,660.56 |
DisclosureSEC source: 0001104659-22-028767 · tm227953-4_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,016 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 55,166 restricted stock units. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033148 · doc4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 530 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033148 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,704 Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 329,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006730 · form4.xml · derivative · entry 10 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,000 Underlying: Common Stock · 329,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 88,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006730 · form4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,660 F2 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 29,500 shares on August 25, 2021, (ii) 29,500 shares on February 25, 2022 and (iii) 29,500 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006730 · form4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,160 F1 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,666 shares on February 25, 2022, (ii) 25,667 shares on February 25, 2023 and (iii) 25,667 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:07 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 4,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029710 · doc4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,174 Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:07 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029710 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,956 Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 127,000 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001104659-20-038882 · a4.xml · derivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 127,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 306,085 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · derivative · entry 9 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,085 Underlying: Common Stock · 306,085 shares Expires 2029-10-02 F2 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 5,000 | $15.00 | $75,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 7 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,000 Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 6 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 1,000 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 5 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 1,000 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 4 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 1,000 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 3 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 1,000 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 1,000 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001140361-19-018070 · form4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 1,000 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| May 16, 2019 Filed May 20, 2019 20:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031429 · doc4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,165 Read SEC document |
| May 16, 2019 Filed May 20, 2019 20:44 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031429 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,418 Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,658 | $0.00 Strike: $21.97 | $0.00 |
DisclosureSEC source: 0001209191-19-029618 · doc4.xml · derivative · entry 3 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,658 shares Expires 2019-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 7,500 shares at an exercise price of $50.78 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015 to 7,829 shares of common stock at an exercise price of $43.93 per share. F3 · derivative.exercise_price: In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. F2 · shares: This option was previously reported as covering 7,500 shares at an exercise price of $50.78 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015 to 7,829 shares of common stock at an exercise price of $43.93 per share. F3 · shares: In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. F4 · derivative.exercise_date: 25% of the stock options vested every quarter from the grant date of 5/19/2011 Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 15,658 | $51.56 | $807,328.05 |
DisclosureSEC source: 0001209191-19-029618 · doc4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,633 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $51.50 to $52.50. Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 15,658 | $21.97 | $343,927.97 |
DisclosureSEC source: 0001209191-19-029618 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:52 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031920 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,633 Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,658 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001209191-18-017221 · doc4.xml · derivative · entry 3 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,658 shares Expires 2018-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the stock options vest every quarter from the grant date of 5/19/2010 F3 · balance_after: This option was previously reported as covering 7,500 shares at an exercise price of $41.75 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015 to 7,829 shares of common stock at an exercise price of $36.12 per share. F4 · balance_after: In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 15,658 | $52.88 | $827,987.21 |
DisclosureSEC source: 0001209191-18-017221 · doc4.xml · nonDerivative · entry 2 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,668 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $52.73 to $53.04. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 15,658 | $18.06 | $282,783.48 |
DisclosureSEC source: 0001209191-18-017221 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2017 Filed May 25, 2017 20:37 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-035423 · doc4.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,668 F1 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date, as reflected in the totals listed on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.